Key Highlights

  • Bio-Path Holdings sold common shares in two tranches under its Tier 1 Regulation A offering, retaining additional funding capacity.
  • The company issued Series B preferred shares to acquire a crypto social platform.
  • Bio-Path must clear overdue payments to restart Phase 2 trials with a cancer center.
  • The company intends to allocate up to 50% of future capital raises to a digital asset treasury.

Bio-Path Holdings has raised capital through two unregistered share sales under its Regulation A offering, leaving additional funding capacity as it scrambles to fund a strategic pivot that now includes crypto investments and AI-driven drug trials. The company issued 466,100 common shares on April 30 for $13,983, followed by 489,200 shares on May 13 for $14,676, both under its qualified Tier 1 Regulation A exemption.

Tiny Equity Sales

Bio-Path has disclosed multiple equity raises, each generating sums that barely cover monthly operating costs. The company’s market capitalization has shrunk, reflecting investor skepticism about its ability to monetize its drug-delivery platform or its pipeline of blood cancer therapies.

Crypto and AI Take Center Stage

In a sharp departure from traditional biotech financing, Bio-Path has allocated up to 50% of future capital raises to a digital asset treasury. The company granted 100,000 common stock purchase warrants to a member of its Advisory Board. The move mirrors a growing trend among small-cap companies in crypto markets.

Partnerships

The company partnered with altFINS to manage its digital asset treasury. The partnership includes a planned issuance of common share equivalents to altFINS and an option to buy a stake in the firm. Bio-Path also partnered with Farrington Capital Group to shop its intellectual property.

Next Catalyst

The most immediate test for Bio-Path is its ability to settle its overdue payments to a cancer center. The cancer center has agreed to restart the Phase 2 trials once the debt is cleared, but the company has not disclosed a concrete plan to raise the funds. On July 6, 2026, Bio-Path issued 22,342 Series B preferred shares.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.